A pharma giant is moving past one patent cliff — but another is already looming
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
Summary from the CNBC news feed. Copyright belongs to CNBC.
Headlines and summaries come from publishers’ public news feeds and are shown with attribution and a link to the original. Investz does not write or endorse them and they are not investment advice. Disclosures.